Objective: Intensive medical treatment of heart failure (HF) patients with diabetes may reduce the endothelial dysfunction and the accelerated atherosclerotic process seen in these patients. To study this, we investigated the endothelial function and the presence of atherosclerosis as measured by flow-mediated vasodilatation (FMD) and intima-media thickness (IMT) in intensively treated patients with coexisting HF and diabetes. Research Design and Method: FMD of the brachial artery and IMT of the common carotid arteries were determined in 26 patients with systolic HF and diabetes who were in intensive medical therapy, as well as in 19 healthy controls. The two groups were matched according to age and sex. In all subjects left ventricular ejection fraction was measured by two-dimensional echocardiography. Biochemical parameters including serum cholesterol, HDL and LDL, triglyceride, glucose, hemoglobin/hemoglobin-A1C (HbA1C), brain natriuretic peptide (BNP) and N-terminal pro-BNP were also assessed. Results: Mean FMD and IMT did not differ significantly between patients and controls. Left ventricular ejection fraction was lower in patients compared to controls (P < 0.001). The patients had a higher mean BNP, NT pro-BNP, triglyceride, HbA1C and glucose in comparison to controls. Cholesterol, HDL-cholesterol and LDL-cholesterol were lower in patients compared to controls. Conclusions: Intensively treated patients with coexisting systolic HF and diabetes seem to have normal endothelial function as measured by FMD and they have no sign of accelerated atherosclerosis as measured by IMT. This suggests a positive effect of medication on the cardiovascular alterations in this group of patients.
References
[1]
Shindler, D.M.; Kostis, J.B.; Yusuf, S.; Quinones, M.A.; Pitt, B.; Stewart, D.; Pinkett, T.; Ghali, J.K.; Wilson, A.C. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (solvd) trials and registry. Am. J. Cardiol. 1996, 77, 1017–1020.
[2]
Domanski, M.; Krause-Steinrauf, H.; Deedwania, P.; Follmann, D.; Ghali, J.K.; Gilbert, E.; Haffner, S.; Katz, R.; Lindenfeld, J.; Lowes, B.D.; et al. The effect of diabetes on outcomes of patients with advanced heart failure in the best trial. J. Am. Coll. Cardiol. 2003, 42, 914–922.
[3]
Dries, D.L.; Sweitzer, N.K.; Drazner, M.H.; Stevenson, L.W.; Gersh, B.J. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 2001, 38, 421–428.
[4]
Ravikumar, R.; Deepa, R.; Shanthirani, C.; Mohan, V. Comparison of carotid intima-media thickness, arterial stiffness, and brachial artery flow mediated dilatation in diabetic and nondiabetic subjects (the chennai urban population study [cups-9]). Am. J. Cardiol. 2002, 90, 702–707.
[5]
Nakamura, M.; Sugawara, S.; Arakawa, N.; Nagano, M.; Shizuka, T.; Shimoda, Y.; Sakai, T.; Hiramori, K. Reduced vascular compliance is associated with impaired endothelium-dependent dilatation in the brachial artery of patients with congestive heart failure. J. Card. Fail. 2004, 10, 36–42.
[6]
Poelzl, G.; Frick, M.; Huegel, H.; Lackner, B.; Alber, H.F.; Mair, J.; Herold, M.; Schwarzacher, S.; Pachinger, O.; Weidinger, F. Chronic heart failure is associated with vascular remodeling of the brachial artery. Eur. J. Heart Fail. 2005, 7, 43–48.
[7]
Niskanen, L.; Rauramaa, R.; Miettinen, H.; Haffner, S.M.; Mercuri, M.; Uusitupa, M. Carotid artery intima-media thickness in elderly patients with niddm and in nondiabetic subjects. Stroke 1996, 27, 1986–1992.
[8]
Rohani, M.; Jogestrand, T.; Ekberg, M.; van der Linden, J.; K？llner, G.; Jussila, R.; Agewall, S. Interrelation between the extent of atherosclerosis in the thoracic aorta, carotid intima-media thickness and the extent of coronary artery disease. Atherosclerosis 2005, 179, 311–316.
[9]
Mattace-Raso, F.; van Popele, N.M.; Schalekamp, M.A.; van der Cammen, T.J. Intima-media thickness of the common carotid arteries is related to coronary atherosclerosis and left ventricular hypertrophy in older adults. Angiology 2002, 53, 569–574.
[10]
Fischer, D.; Rossa, S.; Landmesser, U.; Spiekermann, S.; Engberding, N.; Hornig, B.; Drexler, H. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur. Heart J. 2005, 26, 65–69.
[11]
O'Leary, D.H.; Polak, J.F.; Kronmal, R.A.; Manolio, T.A.; Burke, G.L.; Wolfson, S.K. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular health study collaborative research group. N Engl. J. Med. 1999, 340, 14–22.
[12]
Langford, M.C. Type 2 diabetes and chronic systolic heart failure: Clinical implications. J. Cardiovasc. Nurs. 2004, 19, S35–44. quiz S45-36.
[13]
O'Driscoll, G.; Green, D.; Maiorana, A.; Stanton, K.; Colreavy, F.; Taylor, R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 1999, 33, 1506–1511.
[14]
Mancini, G.B.; Henry, G.C.; Macaya, C.; O'Neill, B.J.; Pucillo, A.L.; Carere, R.G.; Wargovich, T.J.; Mudra, H.; Lüscher, T.F.; Klibaner, M.I.; et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The trend (trial on reversing endothelial dysfunction) study. Circulation 1996, 94, 258–265.
[15]
J？rvisalo, M.J.; Toikka, J.O.; Vasankari, T.; Mikkola, J.; Viikari, J.S.; Hartiala, J.J.; Raitakari, O.T. Hmg coa reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis 1999, 147, 237–242.
[16]
Tan, K.C.; Chow, W.S.; Tam, S.C.; Ai, V.H.; Lam, C.H.; Lam, K.S. Atorvastatin lowers c-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2002, 87, 563–568.
[17]
Mather, K.J.; Verma, S.; Anderson, T.J. Improved endothelial function with metformin in type 2 diabetes mellitus. J. Am. Coll. Cardiol. 2001, 37, 1344–1350.
[18]
Vehkavaara, S.; M？kimattila, S.; Schlenzka, A.; Vakkilainen, J.; Westerbacka, J.; Yki-J？rvinen, H. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb. Vasc. Biol. 2000, 20, 545–550.
[19]
Hodis, H.N.; Mack, W.J.; LaBree, L.; Selzer, R.H.; Liu, C.; Alaupovic, P.; Kwong-Fu, H.; Azen, S.P. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: A randomized controlled clinical trial. Ann. Intern. Med. 1996, 124, 548–556.
[20]
Hosomi, N.; Mizushige, K.; Ohyama, H.; Takahashi, T.; Kitadai, M.; Hatanaka, Y.; Matsuo, H.; Kohno, M.; Koziol, J.A. Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke 2001, 32, 1539–1545.
[21]
Matsumoto, K.; Sera, Y.; Abe, Y.; Tominaga, T.; Yeki, Y.; Miyake, S. Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2004, 64, 225–228.
[22]
Corretti, M.C.; Anderson, T.J.; Benjamin, E.J.; Celermajer, D.; Charbonneau, F.; Creager, M.A.; Deanfield, J.; Drexler, H.; Gerhard-Herman, M.; Herrington, D.; et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the international brachial artery reactivity task force. J. Am. Coll. Cardiol. 2002, 39, 257–265.
[23]
Leeson, P.; Thorne, S.; Donald, A.; Mullen, M.; Clarkson, P.; Deanfield, J. Non-invasive measurement of endothelial function: Effect on brachial artery dilatation of graded endothelial dependent and independent stimuli. Heart 1997, 78, 22–27.
[24]
Berning, J.; Rokkedal Nielsen, J.; Launbjerg, J.; Fogh, J.; Mickley, H.; Andersen, P.E. Rapid estimation of left ventricular ejection fraction in acute myocardial infarction by echocardiographic wall motion analysis. Cardiology 1992, 80, 257–266.
[25]
Bae, J.H.; Bassenge, E.; Kim, M.H.; Park, K.R.; Kim, K.Y.; Synn, Y.C.; Schwemmer, M. Impact of left ventricular ejection fraction on endothelial function in patients with coronary artery disease. Clin. Cardiol. 2004, 27, 333–337.
[26]
Chong, A.Y.; Blann, A.D.; Lip, G.Y. Assessment of endothelial damage and dysfunction: Observations in relation to heart failure. QJM 2003, 96, 253–267.
[27]
Agewall, S. Is impaired flow-mediated dilatation of the brachial artery a cardiovascular risk factor? Curr. Vasc. Pharmacol. 2003, 1, 107–109.
[28]
Maron, D.J.; Fazio, S.; Linton, M.F. Current perspectives on statins. Circulation 2000, 101, 207–213.
[29]
Bu, D.X.; Griffin, G.; Lichtman, A.H. Mechanisms for the anti-inflammatory effects of statins. Curr. Opin. Lipidol. 2011, 22, 165–170.
[30]
Baigent, C.; Keech, A.; Kearney, P.M.; Blackwell, L.; Buck, G.; Pollicino, C.; Kirby, A.; Sourjina, T.; Peto, R.; Collins, R.; et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366, 1267–1278.
[31]
Laufs, U.; La Fata, V.; Plutzky, J.; Liao, J.K. Upregulation of endothelial nitric oxide synthase by hmg coa reductase inhibitors. Circulation 1998, 97, 1129–1135.
[32]
Economides, P.A.; Caselli, A.; Tiani, E.; Khaodhiar, L.; Horton, E.S.; Veves, A. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J. Clin. Endocrinol. Metab. 2004, 89, 740–747.
[33]
Sharrett, A.R.; Patsch, W.; Sorlie, P.D.; Heiss, G.; Bond, M.G.; Davis, C.E. Associations of lipoprotein cholesterols, apolipoproteins a-i and b, and triglycerides with carotid atherosclerosis and coronary heart disease. The atherosclerosis risk in communities (aric) study. Arterioscler Thromb 1994, 14, 1098–1104.
[34]
Bedi, U.S.; Singh, M.; Singh, P.P.; Bhuriya, R.; Bahekar, A.; Molnar, J.; Khosla, S.; Arora, R. Effects of statins on progression of carotid atherosclerosis as measured by carotid intimal—Medial thickness: A meta-analysis of randomized controlled trials. J. Cardiovasc. Pharm. T. 2010, 15, 268–273.
[35]
Simon, A.; Gariepy, J.; Chironi, G.; Megnien, J.L.; Levenson, J. Intima-media thickness: A new tool for diagnosis and treatment of cardiovascular risk. J. Hypertens. 2002, 20, 159–169.
[36]
Beishuizen, E.D.; van de Ree, M.A.; Jukema, J.W.; Tamsma, J.T.; van der Vijver, J.C.; Meinders, A.E.; Putter, H.; Huisman, M.V. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care 2004, 27, 2887–2892.
[37]
Joannides, R.; Bizet-Nafeh, C.; Costentin, A.; Iacob, M.; Derumeaux, G.; Cribier, A.; Thuillez, C. Chronic ace inhibition enhances the endothelial control of arterial mechanics and flow-dependent vasodilatation in heart failure. Hypertension 2001, 38, 1446–1450.
[38]
Ghiadoni, L.; Magagna, A.; Versari, D.; Kardasz, I.; Huang, Y.; Taddei, S.; Salvetti, A. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003, 41, 1281–1286.
[39]
Munakata, M.; Aihara, A.; Nunokawa, T.; Ito, N.; Imai, Y.; Ito, S.; Yoshinaga, K. The influence of one-year treatment by angiotensin converting enzyme inhibitor on baroreflex sensitivity and flow-mediated vasodilation of the brachial artery in essential hypertension—Comparison with calcium channel blockers. Clin. Exp. Hypertens 2003, 25, 169–181.
[40]
Lopez Santi, R.G.; Valeff, E.C.; Duymovich, C.R.; Mazziotta, D.; Mijailovsky, N.E.; Filippa, G.C.; Maltez, R.; Hernandez, V.A.; Monroy, A.G.; Borzi, J.G.; et al. Effects of an angiotensin-converting enzyme inhibitor (ramipril) on inflammatory markers in secondary prevention patients: Raices study. Coron. Artery Dis. 2005, 16, 423–429.
[41]
Wiemer, G.; Sch？lkens, B.A.; Becker, R.H.; Busse, R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991, 18, 558–563.
